Gujarat Themis Biosyn Limited (NSE:GUJTHEM)

Market Cap	32.40B +18.2%
Revenue (ttm)	1.59B +2.7%
Net Income	477.89M -9.2%
EPS	4.39 -9.1%
Shares Out	n/a
PE Ratio	67.79
Forward PE	n/a
Dividend	0.67 (0.22%)
Ex-Dividend Date	Sep 4, 2025

Volume	55,480
Average Volume	71,779
Open	289.10
Previous Close	290.60
Day's Range	282.15 - 304.00
52-Week Range	222.05 - 479.00
Beta	-0.54
RSI	41.50
Earnings Date	Feb 5, 2026

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 221
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUJTHEM

Financial Performance

In fiscal year 2025, Gujarat Themis Biosyn's revenue was 1.51 billion, a decrease of -11.20% compared to the previous year's 1.70 billion. Earnings were 487.72 million, a decrease of -17.56%.